DOCSLIB.ORG

Viatris Group Company Jurisdiction of Incorporation Legal Address Pfizer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Viatris Group Company Jurisdiction of Incorporation Legal Address Pfizer Viatris Group Jurisdiction Legal of Company Address Incorporation Zone Industrielle, Oued Smar, Dar El Pfizer Saidal Manufacturing Algeria Beida, Algiers, Algeria Level 1, 30 The Bond, 30-34 Hickson Agila Australasia Pty Ltd Australia Road, Millers Point NSW 2000, AUSTRALIA, NSW 2000, Australia Level 1, 30 The Bond, 30-34 Hickson Alphapharm Pty. Ltd. Australia Road, Millers Point NSW 2000, AUSTRALIA, NSW 2000, Australia Level 1, 30 The Bond, 30-34 Hickson Mylan Australia Holding Pty Ltd Australia Road, Millers Point NSW 2000, AUSTRALIA, NSW 2000, Australia Level 1, 30 The Bond, 30-34 Hickson Mylan Australia Pty Limited Australia Road, Millers Point NSW 2000, AUSTRALIA, NSW 2000, Australia Level 1, 30 The Bond, 30-34 Hickson Mylan Health Pty. Ltd. Australia Road, Millers Point NSW 2000, AUSTRALIA, NSW 2000, Australia Level 17, 135-151 Clarence St, Sydney Upjohn Australia Pty Ltd. Australia NSW, 2000, Australia Huetteldorfer Strasse 299, Vienna, Arcana Arzneimittel GmbH Austria 1140, Austria MEDA Austria Holding GmbH Austria Guglgasse 15, Vienna, 1110, Austria Meda Pharma GmbH Austria Guglgasse 15, Vienna, 1110, Austria Guglgasse 15, Wien (Vienna), 1110, Mylan Österreich GmbH Austria Austria Terhulpsesteenweg 6A, Hoeilaart, Aktuapharma NV Belgium Belgium, 1560 Park Rozendal, Terhulpsesteenweg Docpharma BVBA Belgium 6A, Hoeilaart, B-1560, Belgium Terhulpsesteenweg 6A, Hoeilaart, Meda Pharma N.V. Belgium Belgium, 1560 Park Rozendal, Terhulpsesteenweg Mylan BVBA Belgium 6A, Hoeilaart, B-1560, Belgium Terhulpsesteenweg 6A, Hoeilaart, Mylan EPD BVBA Belgium Belgium, 1560 Pfizer Innovative Supply Point Hoge Wei 10, Zaventem, 1930, Belgium International BVBA Belgium Boulevard de la Plaine 17, Ixelles, Upjohn SRL Belgium 1050, Belgium 16 Par la Ville Road, Century House, Mylan Bermuda Ltd. Bermuda Hamilton, HM08, Bermuda Bosnia and Kolodvorska 12/3, 71000, Sarajevo, Mylan d.o.o. Herzegovina Bosnia and Herzegovina Mylan Brasil Distribuidora de Rua Nilo Vieira 100, Duque de Caxias, Brazil Medicamentos Ltda. 25020-270, Brazil Estrada Doutor Lourival Martins Beda, 1.118 Bairro Donana, Campos dos Mylan Laboratórios Ltda. Brazil Goytacazes / Rio de Janeiro, 28110- 000 Rua Alexandre Dumas, No. 1860, Upjohn Brasil Importadora e ground floor, room Upjohn, Chácara Brazil Distribuidora de Medicamentos Ltda Santo Antônio, São Paulo, 04717-9, Brazil 48, Sitnyakovo Blvd., Serdika Offices Mylan EOOD Bulgaria building, 7th floor, Sofia, 1505, Bulgaria Suite 900, Purdy's Wharf Tower One, BGP Pharma ULC Canada 1959 Upper Water Street, Halifax, NS, B3J 3N2, Canada 44, Chipman Hill, Suite 1000, P.O. Box Meda Pharmaceuticals Ltd. Canada 7289 Stn. A, Saint John NB, E2L 4S6, Canada 2500, 450 - 1st Street, S.W., Calgary, Mylan Pharmaceuticals ULC Canada AB, T2P 5H1, Canada Suite 1800 - 510 West Georgia Street, Upjohn Canada ULC Canada Vancouver BC, V6B 0M3, Canada Avenida Quilin 5273, Panalolen, Rottapharm Chile SA Chile Santiago, Chile DE1-068, 8th Floor, Block B, No. 18, Xiaguangli, Madaus GmbH China Dongsanhuanbeilu, Chaoyang District, Beijing, China Medicine Meda Pharmaceutical 1001-1004, China Resources Building Information Consultancy (Beijing) Co., China 8, Jianguomenbei Avenue, Dongcheng Ltd. District, Beijing, 10005, China Mylan Pharmaceutical Science and No. 68, Unit 1202, 12 Floor, Yuyuan China Technology (Shanghai) Co., Ltd. Road, Jing'an District, Shanghai, China 22 Daqing Road, Dalian Economic & Pfizer Pharmaceuticals Ltd China Technological Development Zone, Liaoning Province, China Nominal Floor 47, No. 669 Xinzha Pfizer Upjohn Management Co., Ltd. China Road, Shanghai, Jing'an District, China Unit 1004A, 10th Floor, China Resources Building, No. 8 ROTTAPHARM S.P.A. China Jianguomenbeidajie, Dongcheng District, Beijing, China Room 1301, 13F, No. 5, Chaoyangmen Viatris Pharmaceuticals Co., Ltd China North Street, Dongcheng District, Beijing Suite E, 7F, Asia Pacific Tower, No. 2 Viatris Pharmaceuticals Co., Ltd China Hanzhong Road, Gulou District, Nanjing, Jiangsu Province Unit 4, 16F, Jietai Square, No 218-222 Viatris Pharmaceuticals Co., Ltd China Zhongshan 6th Road, Yuexiu District, Guangzhou Koranska, 2, Zagreb, 10 000, Croatia Mylan Hrvatska d.o.o. Croatia 3, Themistokli Dervis, Julia House, Onco Laboratories Limited Cyprus Nicosia, Cyprus, CY-1066, Cyprus Czech Evropská 2590/33c, 160 00 Prague 6, MEDA Pharma s.r.o. Republic Dejvice, Czech Republic Czech Evropská 2590/33c, 160 00 Prague 6, MYLAN HEALTHCARE CZ s.r.o. Republic Dejvice, Czech Republic Czech Evropská 2590/33c, 160 00 Prague 6, Mylan Pharmaceuticals s.r.o Republic Dejvice, Czech Republic 1, Borupvang, Ballerup, 2750, MEDA A/S Denmark Denmark 7, Arne Jacobsens Allé, c/o Regus Mylan ApS Denmark Fairway House, Copenhagen, 2300, Denmark 1, Borupvang, Ballerup, 2750, Mylan Denmark ApS Denmark Denmark Pfizer Africa & Middle East for Pharmaceuticals, Veterinarian Products Egypt 6 October City, Giza, Egypt & Chemicals S.A.E. 147 El Tahrir Street, Dokki, Giza, Pfizer Egypt S.A.E Egypt Postal Code 12311, POB 2357, Cairo, Egypt Pfizer Middle East for Pharmaceuticals, Egypt 147 El Tahrir Street, Dokki, Giza, Egypt Animal Health & Chemicals S.A.E. Meda Oy Finland Vaisalantie 4, Espoo, 02130, Finland Mylan Finland Oy Finland 2-8, Vaisalantie, Espoo, Finland, 02130 Mylan Oy Finland 2-8, Vaisalantie, Espoo, Finland, 02130 Oy Scanmeda Ab Finland Vaisalantie 4, Espoo, 02130, Finland 40/44, rue Washington, Paris, 75008, Laboratoires Madaus S.A.S. France France 40/44, rue Washington, Paris, 75008, Meda Holding S.A.S. France France Avenue du Président Kennedy, BP Meda Manufacturing S.A.S. France 90100, Mérignac Cedex, 33704 40/44, rue Washington, Paris, 75008, Meda Pharma S.A.S. France France 117, Allee des Parcs, Saint Priest, Mylan EMEA S.A.S. France 69800, France 117, Allee des Parcs, Saint Priest, Mylan Generics France Holding S.A.S. France 69800, France Route de Belleville, Châtillon-sur- Mylan Laboratories S.A.S. France Chalaronne, 01400, France 40/44, rue Washington, Paris, 75008, Mylan Medical S.A.S. France France 117, Allee des Parcs, Saint Priest, Mylan S.A.S. France 69800, France 23-25 avenue du Docteur Pfizer PFE France France Lannelongue, Paris, 75014, France 40/44, rue Washington, Paris, 75008, Rottapharm S.A.S. France France 15, Colonia-Allee, Koln, 51067, Erste Madaus Beteiligungs GmbH Germany Germany, Europe 15, Colonia-Allee, Koln, 51067, Galmeda GmbH Germany Germany, Europe KORIN Grundstücksgesellschaft mbH Lütticher Strasse 5, 53842 Troisdorf, Germany & Co. Projekt 31 KG Germany 15, Colonia-Allee, Koln, 51067, Madaus GmbH Germany Germany, Europe Benzstrasse 1, 61352 Bad Homburg v. MEDA Germany Beteiligungs GmbH Germany d. Höhe, Germany Benzstrasse 1, 61352 Bad Homburg v. MEDA Germany Holding GmbH Germany d. Höhe, Germany Neurather Ring 1, Koln, 51063, MEDA Manufacturing GmbH Germany Germany Benzstrasse 1, 61352 Bad Homburg v. MEDA Pharma GmbH & Co. KG Germany d. Höhe, Germany 15, Colonia-Allee, Koln, 51067, MWB Pharma GmbH Germany Germany, Europe Benzstrasse 1, 61352 Bad Homburg v. Mylan dura GmbH Germany d. Höhe, Germany Lütticher Strasse 5, 53842 Troisdorf, Mylan Germany GmbH Germany Germany Lütticher Strasse 5, 53842 Troisdorf, Mylan Healthcare GmbH Germany Germany Lütticher Strasse 5, 53842 Troisdorf, Mylan Pharmaceuticals GmbH Germany Germany Linkstrasse 10, Berlin, 10785, Pfizer OFG Germany GmbH Germany Germany 15, Colonia-Allee, Koln, 51067, Pharmazeutische Union GmbH Germany Germany, Europe 15, Colonia-Allee, Koln, 51067, ROTTAPHARM | MADAUS GmbH Germany Germany, Europe Neurather Ring 1, Koln, 51063, Tropon U-Kasse GmbH Germany Germany Neurather Ring 1, Koln, 51063, Troponwerke GmbH Germany Germany Verwaltungsgesellschaft Neurather Lütticher Strasse 5, 53842 Troisdorf, Germany Ring GmbH Germany Benzstrasse 1, 61352 Bad Homburg v. VIATRIS GmbH Germany d. Höhe, Germany 15, Colonia-Allee, Koln, 51067, Zweite Madaus Beteiligungs GmbH Germany Germany, Europe 57/63, Line Wall Road, PO Box 199, Mylan (Gibraltar) 4 Limited Gibraltar Gibraltar, GX111AA, Gibraltar 57/63, Line Wall Road, PO Box 199, Mylan (Gibraltar) 5 Limited Gibraltar Gibraltar, GX111AA, Gibraltar 57/63, Line Wall Road, PO Box 199, Mylan (Gibraltar) 6 Limited Gibraltar Gibraltar, GX111AA, Gibraltar 57/63, Line Wall Road, PO Box 199, Mylan (Gibraltar) 7 Limited Gibraltar Gibraltar, GX111AA, Gibraltar 57/63, Line Wall Road, PO Box 199, Mylan (Gibraltar) 8 Limited Gibraltar Gibraltar, GX111AA, Gibraltar 57/63, Line Wall Road, PO Box 199, Mylan (Gibraltar) 9 Limited Gibraltar Gibraltar, GX111AA, Gibraltar 63, Agiou Dimitriou Street, Alimos, BGP Pharmaceutical Products Ltd. Greece Attica, 17456, Greece 63, Agiou Dimitriou Street, Alimos, Generics Pharma Hellas Ltd. Greece Attica, 17456, Greece 63, Agiou Dimitriou Street, Alimos, Meda Pharmaceuticals S.A. Greece Attica, 17456, Greece Upjohn Hellas Pharmaceutical Limited 253-255 Mesogion Avenue, Athens, Greece Liability Company 15451, Greece Flat D, 36th Floor Montery Plaza, No. Mylan Pharmaceutical Hong Kong Hong Kong 15 Chong Yip Street, Kwun Tong, Limited Kowloon, Hong Kong Units 3-4, 7/F and 18/F Kerry Centre, Pfizer Upjohn Hong Kong Limited Hong Kong 683 King's Road, Quarry Bay, Hong Kong, Hong Kong Avenida Comercial de Macau, n.s 251A-301, AIA Tower, 17/F, Sala 1702, Pfizer Upjohn Hong Kong Limited Hong Kong em Macau, Hong Kong MEDA PHARMA HUNGARY Hungary 150, Váci út, Budapest, Hungary, 1138 KERESKEDELMI Kft. Mylan EPD Kft. Hungary Vaci Ut 150, Budapest, 1138, Hungary H-2900 Komarom Mylan Street 1, Mylan Hungary Kft. Hungary Komarom, Hungary Mylan Kft. Hungary
Load more

Recommended publications
  • Essex Hangar Aircrafi: Challenger (Schering Plough) Tail Number: N34CD Flight Time: 50 Minutes
    This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu ... DRAFT# 1- 8/26/94 ·- Contact: Mo Taggart 703/684-7848 Jo-Anne Coe 703/845-1714 SENATOR DOLE SCHEDULE ~ AUGUST 30, 1994 -NEW YORK TUESDAY. AUGUST 30 .. 1".4 10:35 am DEPART Capitol for National Airport Ori ver: Wilbert 10:50 am ARRIVE National Airport and proceed to departing aircraft PBO: Signature 703/419·8440 10:55 am DEPART Wushington for Morristown, NJ FBO: Essex Hangar Aircrafi: Challenger (Schering Plough) Tail number: N34CD Flight time: 50 minutes Pilots: Curt Barsi John Santucci Seats: 6 Meal: None Manifest: Senator Dole Rob Lively, Schcring Plough Mike Glassner • Mark Miller Contact: Rob Lively 202/463-8809 11:45 am ARRIVE Morristown, NJ FBO: Essex Hangar 201/539-6554 11 :50 am DEPART airport for Shering Plough Headquarters Driver: Mr. Luciano's driver Drive time: 5 minutes J,ocation: l Giralda Fanns Madison, NJ 11 :55 am ARRIVE Schering Plough Headquarters 20 I /822-7440 Page 1 of 48 This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu TUESDAY, AUGUSI-.3D .1994 PAGE TWO 12:00 N- ATTEND Lunch with Bob Luciano, Chairman of Schering Plough 1:30 pm 1:30 pm DEPART Schering Plough Headquarters for airport Driver: Mr. Luciano's driver Drive time: 5 minutes 1:35 pm ARRIVE airport and proceed to departing heliocopter FBO: Essex Hangar 201/539-6554 1:40 pm DEPART Morristown, NJ for New York Helo pad: 34th Strecf Helo pad Aircraft: S-76 .
    [Show full text]
  • Responding to Mylan's Inadequate Tender Offer
    Responding To Mylan’s Inadequate Tender Offer: Perrigo’s Board Recommends That You Reject the Offer and Do Not Tender September 2015 Important Information Forward Looking Statements Certain statements in this presentation are forward-looking statements. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including future actions that may be taken by Mylan in furtherance of its unsolicited offer. These and other important factors, including those discussed under “Risk Factors” in the Perrigo Company’s Form 10-K for the year ended June 27, 2015, as well as the Company’s subsequent filings with the Securities and Exchange
    [Show full text]
  • Pfizer and Mylan Will Own 57% and 43% of the New Company (“Newco”), Respectively
    DEAL PROFILE PFIZER | MYLAN VALUES 57% 43% $12.0bn PFIZER SHARE OF NEWCO MYLAN SHARE OF NEWCO NEW DEBT RAISED Pfizer Inc. (NYSE:PFE) Pfizer Inc. (“Pfizer”) is a pharmaceutical company that develops, manufactures, and sells products in internal medicine, vaccines, oncology, inflammation & immunology, and rare diseases. Upjohn, a subsidiary of Pfizer, is composed of Pfizer’s oral solid generics and off-patent drugs franchise, such as Viagra, Lipitor, and Xanax. Upjohn has a strong focus in emerging markets, and is headquartered in Shanghai, China. TEV: $265.4bn LTM EBITDA: $22.5bn LTM Revenue: $55.7bn Mylan N.V. (NASDAQ:MYL) Mylan N.V. (“Mylan”) is a pharmaceutical company that develops, manufactures, and commercializes generic, branded-generic, brand-name, and over-the-counter products. The company focuses in the following therapeutic areas: cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Mylan was founded in 1961 and is headquartered in Canonsburg, PA. TEV: $23.9bn LTM EBITDA: $3.5bn LTM Revenue: $11.3bn Bourne Partners provides strategic and financial advisory services to BOURNE clients throughout the business evolution life cycle. In order to provide PARTNERS the highest level of service, we routinely analyze relevant industry MARKET trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, RESEARCH OTC, consumer health, and biotechnology sectors. On July 29, 2019, Pfizer announced the spin-off of its off-patent drug unit, Upjohn, in order to merge the unit with generic drug manufacturer, Mylan.
    [Show full text]
  • Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- Based HIV Treatments in Developing Countries
    December 1, 2014 Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- based HIV Treatments in Developing Countries PITTSBURGH and HYDERABAD, India, Dec. 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs. Tenofovir Alafenamide (TAF) is an investigational antiretroviral drug for the treatment of HIV-1 infection. The license being granted to Mylan extends to 112 countries, which together account for more than 30 million people living with HIV, representing 84% of those infected globally.1 Mylan CEO Heather Bresch said, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines and set new standards in health care. By working with partners like Gilead to help ensure access to innovative new products such as Tenofovir Alafenamide (TAF) in the countries hardest hit by this disease, we can help stem the tide of HIV/AIDS around the world." As part of the licensing agreement, on U.S. Food and Drug Administration (FDA) approval, Mylan will receive a technology transfer from Gilead, enabling the company to manufacture low-cost versions of Tenofovir Alafenamide (TAF), if approved as a single agent or in approved combinations containing Tenofovir Alafenamide (TAF) for developing markets. Phase III trials by Gilead Sciences met their primary objective supporting the potential for Tenofovir Alafenamide (TAF) to provide a new treatment option for individuals living with HIV.
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • Combination Medications
    Combination Medications WHAT ARE COMBINATION MEDICATIONS? Combination medications are pills, tablets, or injections that contain more than one medication to treat HIV. They are listed in the tables below. Pharmaceutical companies have been working hard to make their medications easier to take. Part of this effort has been to combine more than one medication into a single pill. These combinations are referred to as fixed-dose combinations (FDCs). Combinationantiretroviral therapy (ART), sometimes called highly active antiretroviral therapy (HAART), has revolutionized the management of HIV infection and rendered it a chronic manageable disease. The first FDC to treat HIV wasCombivir , manufactured by ViiV Healthcare. Combivir contains two nucleoside reverse transcriptase inhibitors (NRTIs): lamivudine and zidovudine. This was followed byTrizivir , also manufactured by ViiV Healthcare. Trizivir includes three NRTIs:abacavir , lamivudine, and zidovudine. Both Combivir and Trizivir are no longer widely used in the U.S. due to the frequency and severity of side effects. Be sure that you do not take a combination medication along with any of its components!For example, do not take Truvada (which contains emtricitabine and tenofovir DF) with tenofovir DF (Viread) or emtricitabine (Emtriva). Your healthcare provider will help you decide which HAART regimen is best for you; take your medications exactly as your healthcare provider tells you to. TABLE OF COMBINATION HIV MEDICATIONS Brand name Year Approved Individual Components Also Known As Manufacturer
    [Show full text]
  • Eople on the Move Eople on the Move
    eopleeople onon PPthethe movemove Pierre Cloutier Sylvie Denis Gilles Fortin Nicolas Gauvin Bernard Michaud Anna Kratochvil Abbott Abbott Abbott Abbott Abbott Abbott Laboratories Laboratories Laboratories Laboratories Laboratories Laboratories Gary Schmid Alison Shore Eric Bergey Kal Dreisziger Lidia Krupka Abbott Abbott L’Académie- Allard-Johnson Allard-Johnson Laboratories Laboratories Ogilvy Communications Communications (Montreal) (Montreal) Pierre Cloutier, formerly Business Nicolas Gauvin, formerly Senior Alison Shore, formerly Product Unit Manager, Oncology, Product Manager, GI, has been Manager, has been promoted to Pharmaceutical Products Division, promoted to Marketing Manager, GI, Senior Product Manager, Metabolic has been promoted to Director, Pharmaceutical Products Division, at (Meridia), Pharmaceutical Products Customer Relations (Corporate), at Abbott Laboratories. Division, at Abbott Laboratories. Abbott Laboratories. Bernard Michaud, formerly Senior Eric Bergey, formerly International Sylvie Denis, formerly Business Unit Product Manager, Anti-infectives, has OTC Product Manager at World Manager, Cardiovascular & been promoted to Marketing Headquarters of Pharmacia & Metabolic, has been promoted to Manager, Anti-infectives, Upjohn in Sweden and, most Director of Sales, Primary Care, Pharmaceutical Products Division, at recently, Account Supervisor at Jeffrey Pharmaceutical Products Division, at Abbott Laboratories. Simbrow Associates (Montreal), has Abbott Laboratories. been appointed Account Director at Anna Kratochvil,
    [Show full text]
  • Big Pharma Freshens Up
    April 09, 2021 Big pharma freshens up Amy Brown Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol. All successful drug franchises must one day fade – the challenge comes in finding replacements. It is encouraging therefore to see that almost all major developers improved on the sales freshness index last year, versus 2019, with a couple of notable exceptions. This percentage measure is derived from the proportion of a company’s prescription drug sales that come from products more than 10 years old. Scores range widely within the cohort, showing that some groups have much more work to do than others. Take Abbvie, with 74% of 2020’s drug sales derived from drugs at least a decade old, compared with a much fresher Astrazeneca, at 44%. Abbvie is still very reliant on its mega-blockbuster Humira – the autoimmune antibody contributed 44% of the company’s drugs sales last year – and the big pharma group’s freshness score has not shifted from 2019, when Evaluate Vantage last ran these numbers (Sanofi's geriatric pipeline fails to freshen up, January 22, 2020). Astrazeneca was at the other end of the scale last time and its performance improved again in 2020. The previous laggard Sanofi, meanwhile, has the huge success of Dupixent to thank for its big shift towards the fresher end of the group. The French company’s departure from the top of the table leaves Abbvie, Pfizer and Roche as the stalest big pharma groups, and arguably under the most pressure to find new sales sources.
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Fellow Shareholders, Since Perrigo Company
    Fellow Shareholders, Since Perrigo Company plc (NYSE and TASE: PRGO) rejected Mylan N.V.’s (NASDAQ: MYL) unsolicited offer, I have spent a great deal of time speaking with our shareholders and sharing our views on why Mylan’s offer substantially undervalues Perrigo. We are confident in our bright prospects and firmly convinced of the standalone value of Perrigo. I have also engaged with you not only about value, but also about the right way to run a company. I have always believed that good corporate governance creates value for shareholders while bad corporate governance can destroy it. Since becoming the CEO of the Perrigo Company, I have had the privilege of working alongside a Board that shares my commitment to shareholder value creation and sound corporate governance. Together, we believe deeply in our responsibility to shareholders, who are Perrigo’s true owners, and in our obligation to build sustainable, long-term value, which informs everything we do. This commitment has rewarded Perrigo shareholders with a total return exceeding 970 percent since 2007. I have watched with increasing distress the contrast in attitude to shareholders and governance principles that Mylan has presented in its pursuit of Perrigo. Our Board has considered Mylan’s offer in good faith and we have been earnest and straightforward in explaining why we think it substantially undervalues Perrigo and creates significant risks. We have also engaged with you to explain how Perrigo’s ‘Base Plus, Plus, Plus’ strategy is poised to continue to create value in the future for our shareholders. In recent weeks, it has become clear to me that Mylan’s pursuit of Perrigo at all costs has further highlighted some very troubling corporate governance values.
    [Show full text]
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
    [Show full text]
  • Johnson & Johnson and Pfizer Inc., Analysis of Agreement Containing
    ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS TO AID PUBLIC COMMENT In the Matter of Johnson & Johnson and Pfizer Inc. File No. 061-0220, Docket No. C-4180 I. Introduction The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Johnson & Johnson (“J&J”) and Pfizer Inc. (“Pfizer”), which is designed to remedy the anticompetitive effects that would otherwise result from J&J’s proposed acquisition of Pfizer Consumer Healthcare. Under the terms of the proposed Consent Agreement, the parties will be required to divest: (1) Pfizer’s Zantac® H-2 blocker business; (2) Pfizer’s Cortizone® hydrocortisone anti-itch business; (3) Pfizer’s Unisom® nighttime sleep-aid business; and (4) J&J’s Balmex® diaper rash treatment business. The proposed Consent Agreement has been placed on the public record for thirty (30) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the proposed Consent Agreement and will decide whether it should withdraw from the proposed Consent Agreement, modify it, or make final the Decision and Order (“Order”). Pursuant to a Stock and Asset Purchase Agreement dated June 25, 2006, J&J proposes to acquire certain voting securities and assets comprising Pfizer’s Consumer Healthcare business in a transaction valued at approximately $16.6 billion (“Proposed Acquisition”). The Commission’s complaint alleges that the Proposed Acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C.
    [Show full text]